Headache in systemic lupus erythematosus: Results from a prospective, international inception cohort study

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2887-2897

  Hanly, John G ^a   Urowitz, Murray B ^b   O'Keeffe, Aidan G ^c   Gordon, Caroline ^d   Bae, Sang Cheol ^e   Sanchez Guerrero, Jorge ^b   Romero Diaz, Juanita ^f   Clarke, Ann E ^g   Bernatsky, Sasha ^g   Wallace, Daniel J ^h   Ginzler, Ellen M ⁱ   Isenberg, David A ^j   Rahman, Anisur ^j   Merrill, Joan T ^k   Petri, Michelle ^l   Fortin, Paul R ^m   Gladman, Dafna D ^b   Fessler, Barri J ⁿ   Alarcõn, Graciela S ⁿ   Bruce, Ian N ^o   Dooley, Mary Anne ^p   Steinsson, Kristjan ^q   Khamashta, Munther A ^r   Ramsey Goldman, Rosalind ^s   Manzi, Susan ^t   Sturfelt, Gunnar K ^u   Nived, Ola ^u   Zoma, Asad A ^v   Van Vollenhoven, Ronald F ^w   Ramos Casals, Manuel ^x   Aranow, Cynthia ^y   Mackay, Meggan ^y   Ruiz Irastorza, Guillermo ^z   Kalunian, Kenneth C ^aa   Lim, S Sam ^ab   Inanc, Murat ^ac   Kamen, Diane L ^ad   Peschken, Christine A ^ae   Jacobsen, Soren ^af   Theriault, Chris ^a   Thompson, Kara ^a   Farewell, Vernon ^c   more..

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^f INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m LAVAL UNIVERSITY   (Canada)

ⁿ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p UNIVERSITY OF NORTH CAROLINA   (United States)

^q LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^r ST THOMAS HOSPITAL   (United Kingdom)

^s NORTHWESTERN UNIVERSITY   (United States)

^t UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^u LUND UNIVERSITY HOSPITAL   (Sweden)

^v HAIRMYRES HOSPITAL   (United Kingdom)

^w KAROLINSKA INSTITUTE   (Sweden)

^x HOSPITAL CLÍNIC   (Spain)

^y FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^z UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^aa UNIVERSITY OF CALIFORNIA   (United States)

^ab EMORY UNIVERSITY   (United States)

^ac ISTANBUL UNIVERSITY   (Turkey)

^ad MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^ae UNIVERSITY OF MANITOBA   (Canada)

^af Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADULT; ARTICLE; CLUSTER HEADACHE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NEUROPSYCHIATRY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SYSTEMIC LUPUS ERYTHEMATOSUS; TENSION HEADACHE;

ADULT; AUTOANTIBODIES; CLUSTER HEADACHE; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; INTERNATIONALITY; INTRACRANIAL HYPERTENSION; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TENSION-TYPE HEADACHE; YOUNG ADULT;

EID: 84886776750     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38106     Document Type: Article

References (41)

1. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A,. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500.
2. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214-20.
3. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K,. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 2156-62.
4. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Mathieu A, Hughes GR,. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-92.
5. Sibbitt WL Jr, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29: 1536-42.
6. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al, for the Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007; 56: 265-73.
7. Hanly JG,. The nervous system and lupus. In:, Lahita RG, Tsokos G, Buyon J, Koike T, editors. Systemic lupus erythematosus. 5th ed. Philadelphia: Elsevier; 2011. p. 727-46.
8. Mitsikostas DD, Sfikakis PP, Goadsby PJ,. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004; 127: 1200-9.
9. Amit M, Molad Y, Levy O, Wysenbeek AJ,. Headache in systemic lupus erythematosus and its relation to other disease manifestations. Clin Exp Rheumatol 1999; 17: 467-70.
10. Abel T, Gladman DD, Urowitz MB,. Neuropsychiatric lupus. J Rheumatol 1980; 7: 325-33.
11. Gladman DD, Ibanez D, Urowitz MB,. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288-91.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
13. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 902-6.
14. Isenberg D, Ramsey-Goldman R,. Systemic Lupus International Collaborating Group-onwards and upwards? Lupus 2006; 15: 606-7.
15. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
16. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
17. ACR Ad Hoc Committee on Neuropsychiatric Lupus Syndromes. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7: 1-96.
19. Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, Gordon C, et al, for the Systemic Lupus International Collaborating Clinics. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008; 59: 721-9.
20. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001; 45: 419-23.
21. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 961-7.
22. Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Thio ST, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999; 26: 97-102.
23. 2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999; 81: 748-57.
24. Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB,. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24: 1083-8.
25. 2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002; 11: 215-20.
26. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, et al, for the Systemic Lupus International Collaborating Clinics. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58: 843-53.
27. Cox DR,. Regression models and life-tables (with discussion). J Royal Stat Soc B 1972; 34: 187-220.
28. Liang KY, Seger S,. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
29. Galego JC, Moraes AM, Cordeiro JA, Tognola WA,. Chronic daily headache: stress and impact on the quality of life. Arq Neuropsiquiatr 2007; 65: 1126-9.
30. De Filippis S, Erbuto D, Gentili F, Innamorati M, Lester D, Tatarelli R, et al. Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. J Headache Pain 2008; 9: 349-57.
31. Autret A, Roux S, Rimbaux-Lepage S, Valade D, Debiais S,. Psychopathology and quality of life burden in chronic daily headache: influence of migraine symptoms. J Headache Pain 2010; 11: 247-53.
32. Stovner LJ, Andree C,. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010; 11: 289-99.
33. Rasmussen BK, Jensen R, Schroll M, Olesen J,. Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol 1991; 44: 1147-57.
34. Weder-Cisneros ND, Tellez-Zenteno JF, Cardiel MH, Guibert-Toledano M, Cabiedes J, Velasquez-Paz AL, et al. Prevalence and factors associated with headache in patients with systemic lupus erythematosus. Cephalalgia 2004; 24: 1031-44.
35. Sheffield RE,. Migraine prevalence: a literature review. Headache 1998; 38: 595-601.
36. Isenberg DA, Meyrick-Thomas D, Snaith ML, McKeran RO, Royston JP,. A study of migraine in systemic lupus erythematosus. Ann Rheum Dis 1982; 41: 30-2.
37. Whitelaw DA, Hugo F, Spangenberg JJ, Rickman R,. Headaches in patients with systemic lupus erythematosus: a comparative study. Lupus 2004; 13: 501-5.
38. Fernandez-Nebro A, Palacios-Munoz R, Gordillo J, Abarca-Costalago M, De Haro-Liger M, Rodriguez-Andreu J, et al. Chronic or recurrent headache in patients with systemic lupus erythematosus: a case control study. Lupus 1999; 8: 151-6.
39. Davey R, Bamford J, Emery P,. The validity of the inclusion of "lupus headache" in the Systemic Lupus Erythematosus Disease Activity Index [letter]. Arthritis Rheum 2007; 56: 2812-3.
40. Thumboo J, Fong KY, Chan SP, Leong KH, Feng PH, Thio ST, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000; 27: 1414-20.
41. Strand V, Crawford B,. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005; 5: 317-26.